Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 56 The GLP-1 segment accounts for 9% of the total diabetes care market in Europe European GLP-1 market VictozaⓇ value market share in Europe GLP-1 value in bDKK VictozaⓇ dulaglutide lixisenatide exenatide Share of total GLP-1 value diabetes care market market share VictozaⓇ dulaglutide - exenatide - lixisenatide 100% 6 12% CAGR value¹: 21.7% 5 10% 80% 68% 4 + 8% 60% 3 - 6% 40% 2 4% 20% 1 2% 0% 0% Aug 2011 1 CAGR for 5-year period Source: IMS Monthly MAT August, 2016 value figures (DKK) Aug Aug 2011 Aug 2016 2016 Source: IMS Monthly MAT August, 2016 value figures (DKK) changing diabetes® novo nordisk

View entire presentation